Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapyJ Immunother Cancer 2022 Jun 01;10(6)xx, GH Attrill, CN Owen, T Ahmed, IA Vergara, AJ Colebatch, JW Conway, KJ Nahar, JF Thompson, I Pires da Silva, MS Carlino, AM Menzies, S Lo, U Palendira, RA Scolyer, GV Long, JS Wilmott
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.